跳至主要内容
临床试验/CTRI/2020/06/026076
CTRI/2020/06/026076尚未招募不适用

A cross-sectional (baseline) & observational real world study on newly diagnosed patients with type 2 diabetes in India

Eris Lifesciences Ltd1 个研究点 分布在 1 个国家目标入组 13,000 人开始时间: 2020年1月7日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
13,000
试验地点
1
主要终点
To characterise/type/profile the newly diagnosed Indian patient with type 2 diabetes from the demographic details and laboratory investigations

研究概览

简要总结

Over the past few decades, various studies have been done to attempt to estimate the prevalence of diabetes in India. But till now no study has been done to characterize and classify newly detected type 2 diabetic population.

The purpose of the study to characterize/type/profile the newly diagnosed Indian patient with type 2 diabetes from the demographic details and baseline investigations.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Adult patients (Aged 18 Years or above) who were newly diagnosed with type 2 diabetes and referred to the clinic within 1 year of diagnosis.
  • Diagnosis of diabetes will be based on American Diabetes Association criteria.

排除标准

  • Monogenic diabetes syndrome
  • Disease of the exocrine pancreas
  • Gestational Diabetes
  • Acute or severe chronic heart disease
  • Renal or psychiatric disease.
  • Initial evaluation in clinic after 1 year of diagnosis or unclear at time of diagnosis, type 1, type 1.5, or type 3 diabetes.

结局指标

主要结局

To characterise/type/profile the newly diagnosed Indian patient with type 2 diabetes from the demographic details and laboratory investigations

时间窗: 1 Year

次要结局

  • NA(NA)

研究者

发起方
Eris Lifesciences Ltd
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验

Observational study on newly diagnosed type 2... | 临床试验